Drugs / Tibulizumab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03736772 | Nov 2018 → Mar 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02614716 | Dec 2015 → Sep 2018 | Sjogren syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01925157 | Aug 2013 → Jan 2015 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06993610 | May 2025 → Nov 2026 expected | hidradenitis suppurativa | Zura Bio Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06843239 | Feb 2025 → May 2027 expected | systemic sclerosis | Zura Bio Inc | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04563195 | Feb 2022 → Dec 2023 | Sjogren syndrome | Matthew C. Baker | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tibulizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06843239 ↗ |
| Known as | LY3090106 | “To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's...” NCT04563195 ↗ |
| Action | Inhibit | “Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL3990000 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3990000 ↗ |
| Route | Subcutaneous | “Administered SQ.” NCT01925157 ↗ |
| Target | IL17A | “Interleukin 17A inhibitor” CHEMBL3990000 ↗ |
| Target | TNFSF13B | “Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL3990000 ↗ |